Screening and identification of a novel hepatocellular carcinoma cell binding peptide by using a phage display library

Abstract

The purpose of this study was to screen peptides that can specifically bind to human hepatocellular carcinoma (hHCC) cells using phage display of random peptide library in order to develope a peptide-based carrier for the diagnosis or therapy of hHCC. A peptide 12-mer phage display library was employed and 4 rounds of subtractive panning were performed using the hHCC cell line HepG2 as the target. After panning, the phages that specifically bound to and internalized in hHCC cells were selected. The selected phages demonstrated highly specific affinity to HepG2 cells analyzed by ELISA and immunofluorescence analysis. 57.3% of the selected phage clones displayed repeated sequence FLLEPHLMDTSM, and 4 amino acid residues, FLEP were extremely conservative. Based on the sequencing results, a 16-mer peptide (WH-16) was synthesized. The competitive ELISA showed that the binding of the phage clones displayed sequence FLLEPHLMDTSM to HepG2 cells was efficiently inhibited by WH-16. Our findings indicate that cellular binding of phage is mediated via its displayed peptide and the synthesized 16-mer peptide may have the potential to be a delivery carrier in target diagnosis or therapy for hHCC.

Keywords

phage display of random peptide library / hepatocellular carcinoma / peptides / biologic targeting delivery

References

[1] JainR. K.. The next frontier of molecular medicine: delivery of therapeutics. Nat Med, 1998, 4: 655-657

[2] BarryM. A., DowerW. J., JohnstonS. A.. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med, 1996, 2: 299-305

[3] ReubiJ. C.. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev, 2003, 24: 389-427

[4] WeinerR. E., ThakurM. L.. Radiolabeled peptides in diagnosis and therapy. Semi Nucl Med, 2001, 4: 296-311

[5] WekkeboomD., KrenningE. P., de JoneM.. Peptide receptor imaging and therapy. J Nucl Med, 2000, 41: 1704-1713

[6] PoulM. A., MarksJ. D.. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol, 1999, 288: 201-203

[7] HaubnerR., WesterH. J., BurkhartF., et al.. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med, 2001, 42: 326-336

[8] KuhnastB., BodensteinC., HaubnerR., et al.. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nucl Med Biol, 2004, 31: 337-344

[9] CwirlaS. E., PeterE. A., BarretR. W., et al.. Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci USA, 1990, 87: 6378-6382

[10] SmithG. P.. Surface display and peptide libraries. Gene, 1993, 128: 1-2

[11] SmithG. P., PetrenkoV. A.. Phage display. Chem Rev, 1997, 97: 391-410

[12] KoivunenE., ArapW., RajotteD., et al.. Identification of receptor ligands with phage display peptide libraries. J Nucl Med, 1999, 40: 883-888

[13] LandonL. A., DeutscherS. L.. Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem, 2003, 90: 509-517

[14] ZitzmannS., MierW., SchadA., et al.. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res, 2005, 11: 139-146

[15] YayonA., DavidA., MichalS., et al.. Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library. Proc Natl Acad Sci USA, 1993, 90: 10643-10647

[16] RajotteD., ArapW., HagedornM., et al.. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Inves, 1998, 102: 430-437

[17] PasqualiniR., RuoslahtiE.. Organ targeting in vivo using phage display peptide libraries. Nature, 1996, 380: 364-366

[18] ArapW., PasqualiniR., RuoslahtiE.. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse mode. Science, 1998, 279: 377-380

[19] BurgM. A., PasqualiniR., ArapW., et al.. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res, 1999, 59: 2869-2874

[20] GhoY. S., LeeJ. E., KyoungS. O., et al.. Development of antiangiogenin peptide using a phage-displayed peptide library. Cancer Res, 1997, 57: 3733-3740

[21] IvanenkovW., FeliciF., MenonA. G.. Targeted delivery of multivalent phage display vectore into mammalian cells. Biochem Biophys Acta, 1999, 1448: 463-472

[22] MazzucchelliL., BurrittJ. B., JesaitisA. J., et al.. Cell-specific peptide binding by human neutrophils. Blood, 1999, 93: 1738-1748

[23] HongF. D., ClaymanG. L.. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res, 2000, 60: 6551-6556

[24] ZhangJ. B., SpringH., SchwabM.. Neuroblastoma tumor cell-binding pepties identified through random peptide phage display. Cancer Lett, 2001, 171: 153-164

[25] AskoxylakisV., MierW., ZitzmannS., et al.. Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. J Nucl Med, 2006, 47: 981-988

[26] WellingsD. A., AthertonE.. Standard Fmoc protocols. Methods Enzymol, 1997, 289: 44-67

[27] BerdichevskyY., Ben-ZeevE., LamedR., et al.. Phage display of a cellulose binding domain from Clostridum thermocellum and its application as a tool for antibody engineering. J Immunol Methods, 1999, 228: 151-162

[28] KamenB. A., CapdevilaA.. Receptor mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA, 1986, 83: 5983-5987

[29] LeamonC. P., LowP. S.. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA, 1991, 88: 5572-5576

[30] KassnerP. D., BurgM. A., BairdA., et al.. Genetic selection of phage engineered for receptor mediated gene transfer to mammalian cells. Biochem Biophys Res Commu, 1999, 264: 921-928